AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9383135 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 1312233 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril + Hydrochlorothiazide (LIS + HCTZ)
Number of subjects: 175
Study 1312233 — intervention group
Group type: COMPARATOR
Intervention: Captopril + Hydrochlorothiazide (CAP + HCTZ)
Number of subjects: 175
Study 3900906 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf lung surfactant extract (3 mL, 90 mg) instilled into trachea before the first breath
Number of subjects: 27
Study 3900906 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (3 mL)
Number of subjects: 27
Study 29721850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel (10 mg/kg and 75 mg/m2 every 3 weeks)
Number of subjects: 376
Study 29721850 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 376
Study 29721850 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab exposure (Cave,ss)
Number of subjects: 376
Study 27055228 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) using a 660-nm laser (200 mW, 6 J per point at 4 points) and an 810-nm laser (200 mW, 6 J per point at 3 points) applied on days 2 and 4 after surgery
Number of subjects: 40
Study 27055228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (laser simulation)
Number of subjects: 40
Study 24637789 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan 20 mg
Number of subjects: 700
Study 24637789 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 700
Study 23768024 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet joint resection and L4-5 fusion
Number of subjects: 120
Study 23768024 — intervention group
Group type: EXPERIMENTAL
Intervention: Semilaminectomy and fusion
Number of subjects: 120
Study 23768024 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete laminectomy and fusion
Number of subjects: 120
Study 19897430 — intervention group
Group type: EXPERIMENTAL
Intervention: Asteame Nipple Guard™
Number of subjects: 22
Study 19897430 — intervention group
Group type: COMPARATOR
Intervention: Standard gauze dressing
Number of subjects: 22
Study 17943639 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin tablets 0.6 mg
Number of subjects: 154
Study 17943639 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin nasal spray 20 microg
Number of subjects: 154
Study 17943639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 17943639 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin tablets and spray
Number of subjects: 154
Study 17943639 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin tablets
Number of subjects: 154
Study 17943639 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin tablets and nasal spray
Number of subjects: 154
Study 16900609 — intervention group
Group type: EXPERIMENTAL
Intervention: RLAI
Number of subjects: 50
Study 14674881 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing (experimental group)
Number of subjects: 29
Study 14674881 — intervention group
Group type: COMPARATOR
Intervention: Distraction (control group)
Number of subjects: 29
Study 12202502 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive addition lenses (PAL; add +1.50 D)
Number of subjects: 298
Study 12202502 — intervention group
Group type: COMPARATOR
Intervention: Single vision lenses (SV)
Number of subjects: 298
Study 10344365 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated peritoneal dialysis (APD)
Number of subjects: 36
Study 10344365 — intervention group
Group type: COMPARATOR
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 36
Study 8544145 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2202190 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 41
Study 2202190 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone-Isoflurane
Number of subjects: 41
Study 7047170 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 22
Study 7047170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31039806 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of donepezil for 4 weeks before escalating to 23 mg (group 1)
Number of subjects: 175
Study 31039806 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg and 23 mg on alternate days for 4 weeks prior to escalation (group 2)
Number of subjects: 175
Study 31039806 — intervention group
Group type: COMPARATOR
Intervention: Direct escalation to 23 mg (group 3)
Number of subjects: 175
Study 27714945 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard 40 Hz stimulation
Number of subjects: 29
Study 27714945 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-standard stimulation (500 Hz, 1200 Hz, burst)
Number of subjects: 29
Study 27714945 — intervention group
Group type: COMPARATOR
Intervention: Placebo stimulation
Number of subjects: 29
Study 27714945 — intervention group
Group type: EXPERIMENTAL
Intervention: All SCS settings (standard and non-standard)
Number of subjects: 29
Study 26302879 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 109
Study 26302879 — intervention group
Group type: COMPARATOR
Intervention: Control (no octreotide)
Number of subjects: 109
Study 25213159 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication plus supportive care
Number of subjects: 88
Study 25213159 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo plus supportive care
Number of subjects: 88
Study 25213159 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 88
Study 21946121 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐CPB with triamcinolone and bupivacaine
Number of subjects: 40
Study 21946121 — intervention group
Group type: COMPARATOR
Intervention: EUS‐CPB with only bupivacaine (control)
Number of subjects: 40
Study 19614878 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized nursing intervention protocol to minimize maternal-infant separation
Number of subjects: 50
Study 19614878 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 50
Study 17565841 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided four points via one-puncture technique (Group U)
Number of subjects: 80
Study 17565841 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator-guided brachial plexus blocking (Group N)
Number of subjects: 80
Study 14741163 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vaccines
Number of subjects: 1497
Study 14741163 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV vaccines with recombinant envelope subunit vaccine
Number of subjects: 1497
Study 12487338 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (HII) involving feedback, a physician liaison, and quality improvement tools
Number of subjects: 32
Study 12487338 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity intervention (LII) with written feedback
Number of subjects: 32
Study 12487338 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (HII and LII)
Number of subjects: 32
Study 12487338 — intervention group
Group type: EXPERIMENTAL
Intervention: HII
Number of subjects: 32
Study 10052667 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline infusion for 1 hour
Number of subjects: 8
Study 7972815 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional coronary MR angiography
Number of subjects: 20
Study 2595645 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmion (gr P)
Number of subjects: 15
Study 2595645 — intervention group
Group type: COMPARATOR
Intervention: Haemaccel (gr H)
Number of subjects: 15
Study 4422521 — intervention group
Group type: EXPERIMENTAL
Intervention: Masturbatory and coital stimuli
Number of subjects: 60
Study 4422521 — intervention group
Group type: EXPERIMENTAL
Intervention: Coital stimulus
Number of subjects: 60
Study 31978593 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon ablation
Number of subjects: 346
Study 31978593 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force-guided radiofrequency ablation (CF-RF)
Number of subjects: 346
Study 31978593 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (CF-RF and cryoballoon)
Number of subjects: 346
Study 28689794 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ grass sublingual immunotherapy tablet
Number of subjects: 812
Study 28689794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 812
Study 26585118 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 40
Study 26585118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25335439 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based systematic review workflow platform (ReGroup)
Number of subjects: 0
Study 25335439 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper
Number of subjects: 0
Study 25335439 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile screening application (Screen2Go)
Number of subjects: 0
Study 25335439 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference management software program (EndNote)
Number of subjects: 0
Study 25335439 — intervention group
Group type: COMPARATOR
Intervention: Web-based platform
Number of subjects: 0
Study 23913463 — intervention group
Group type: EXPERIMENTAL
Intervention: SIELLO T steroid‐eluting ventricular leads
Number of subjects: 139
Study 23913463 — intervention group
Group type: EXPERIMENTAL
Intervention: SIELLO JT steroid‐eluting atrial leads
Number of subjects: 139
Study 23913463 — intervention group
Group type: COMPARATOR
Intervention: BPPU T non‐steroid leads
Number of subjects: 139
Study 23913463 — intervention group
Group type: COMPARATOR
Intervention: BPPU JT non‐steroid leads
Number of subjects: 139
Study 20567807 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive cues validly cued (lateral force applied in the same direction as the visual target)
Number of subjects: 0
Study 20567807 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive cues invalidly cued (lateral force applied in the opposite direction to the visual target)
Number of subjects: 0
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended low-intensity anticoagulant therapy (INR 1.5-1.9)
Number of subjects: 661
Study 18791166 — intervention group
Group type: COMPARATOR
Intervention: Conventional-intensity anticoagulant therapy (INR 2.0-3.0)
Number of subjects: 661
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of factor V Leiden
Number of subjects: 661
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: 20210G>A prothrombin gene mutation
Number of subjects: 661
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin deficiency
Number of subjects: 661
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated factor VIII
Number of subjects: 661
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated factor XI
Number of subjects: 661
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated homocysteine
Number of subjects: 661
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibody
Number of subjects: 661
Study 18791166 — intervention group
Group type: EXPERIMENTAL
Intervention: One or more thrombophilic defects
Number of subjects: 661
Study 16649864 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing or talking about a negative experience for 15 min each during 3 consecutive days
Number of subjects: 319
Study 16649864 — intervention group
Group type: COMPARATOR
Intervention: Thinking about a negative experience
Number of subjects: 319
Study 16649864 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about a positive experience (happiest day)
Number of subjects: 319
Study 16649864 — intervention group
Group type: COMPARATOR
Intervention: Replaying a positive experience (happiest day)
Number of subjects: 319
Study 16649864 — intervention group
Group type: EXPERIMENTAL
Intervention: Analyzing the happiest moments
Number of subjects: 319
Study 16649864 — intervention group
Group type: COMPARATOR
Intervention: Repetitively replaying the happiest moments
Number of subjects: 319
Study 12579548 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered psychosocial treatments (manual- and multimedia-based treatments)
Number of subjects: 0
Study 12579548 — intervention group
Group type: COMPARATOR
Intervention: Self-administered psychosocial treatments (inspirational literature and support groups)
Number of subjects: 0
Study 10731864 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (1 mg/kg/d) (Group B)
Number of subjects: 116
Study 10731864 — intervention group
Group type: COMPARATOR
Intervention: Complementary food besides breast-feeding (Group A)
Number of subjects: 116
Study 9209245 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 30 mg/kg
Number of subjects: 30
Study 9209245 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 15 mg/kg
Number of subjects: 30
Study 9209245 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 3 mg/kg
Number of subjects: 30
Study 9209245 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 8141177 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) and prednisolone (P)
Number of subjects: 112
Study 8141177 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (Cs) and prednisolone (P)
Number of subjects: 112
Study 3527997 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine tidiacicate (ATCA) at a dose of 400 mg tablets three times a day for 30 days
Number of subjects: 50
Study 3527997 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 30 days
Number of subjects: 50
Study 2659736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (mean dose 7.2 mg/kg/day)
Number of subjects: 0
Study 2659736 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin (mean dose 5 mg/kg/day)
Number of subjects: 0
Study 2659736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 0
Study 31047956 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACEi)
Number of subjects: 624
Study 31047956 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor blocker (ARB)
Number of subjects: 624
Study 31047956 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEi
Number of subjects: 624
Study 31047956 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB
Number of subjects: 624
Study 28111466 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide/Bortezomib (TV)
Number of subjects: 271
Study 28111466 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (T)
Number of subjects: 271
Study 28111466 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfa‐2b interferon (alfa2‐IFN)
Number of subjects: 271
Study 25468387 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 149
Study 25468387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 23180178 — intervention group
Group type: EXPERIMENTAL
Intervention: THC/CBD spray
Number of subjects: 339
Study 23180178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 339
Study 20957342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBOT)
Number of subjects: 75
Study 20957342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 19559419 — intervention group
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE) with targeted biopsy
Number of subjects: 0
Study 19559419 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopy with a 4-quadrant biopsy protocol
Number of subjects: 0
Study 16912060 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH
Number of subjects: 48
Study 16912060 — intervention group
Group type: EXPERIMENTAL
Intervention: CRH
Number of subjects: 48
Study 16912060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12151445 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified urinary FSH (150 IU starting dose)
Number of subjects: 100
Study 12151445 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (100 mg/day from day 5-10 of the ovarian cycle)
Number of subjects: 100
Study 12151445 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH after failure with CC
Number of subjects: 100
Study 12151445 — intervention group
Group type: EXPERIMENTAL
Intervention: CC followed by FSH if pregnancy not obtained
Number of subjects: 100
Study 10631418 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced Laryngeal Mask Airway (RLMA)
Number of subjects: 60
Study 10631418 — intervention group
Group type: COMPARATOR
Intervention: Standard Laryngeal Mask Airway (LMA)
Number of subjects: 60
Study 10631418 — intervention group
Group type: COMPARATOR
Intervention: LMA
Number of subjects: 60
Study 10631418 — intervention group
Group type: EXPERIMENTAL
Intervention: RLMA
Number of subjects: 60
Study 10631418 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LMA and RLMA
Number of subjects: 60
Study 8536775 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 50 mg daily
Number of subjects: 245
Study 8536775 — intervention group
Group type: COMPARATOR
Intervention: Castration (medical or surgical)
Number of subjects: 245
Study 1943929 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients referred from 24 hour medical centres
Number of subjects: 246
Study 1943929 — intervention group
Group type: COMPARATOR
Intervention: General practitioners' referral letters
Number of subjects: 246
Study 7025508 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 39
Study 7025508 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 39
Study 30897305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg and caffeine 100 mg (FDC)
Number of subjects: 36
Study 30897305 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen lysinate
Number of subjects: 36
Study 30897305 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen lysinate (postprandial)
Number of subjects: 36
Study 28789559 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei NCC 2461 ST11 (1×10^9 cfu)
Number of subjects: 60
Study 28789559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 26270341 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying chromoendoscopy (MC)
Number of subjects: 70
Study 26270341 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS)
Number of subjects: 70
Study 23113573 — intervention group
Group type: EXPERIMENTAL
Intervention: News frame: crime
Number of subjects: 523
Study 23113573 — intervention group
Group type: EXPERIMENTAL
Intervention: News frame: economic contribution
Number of subjects: 523
Study 23113573 — intervention group
Group type: EXPERIMENTAL
Intervention: News frame: crime with Moroccan origin
Number of subjects: 523
Study 23113573 — intervention group
Group type: EXPERIMENTAL
Intervention: Attitude to immigration
Number of subjects: 523
Study 21705864 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 508
Study 21705864 — intervention group
Group type: COMPARATOR
Intervention: Health education group
Number of subjects: 508
Study 18422814 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol plus irbesartan (step-up dosage titration up to 300 mg/d)
Number of subjects: 32
Study 18422814 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (20 mg b.i.d.) plus placebo
Number of subjects: 32
Study 16495006 — intervention group
Group type: COMPARATOR
Intervention: Attention condition
Number of subjects: 223
Study 16495006 — intervention group
Group type: COMPARATOR
Intervention: Distraction condition
Number of subjects: 223
Study 16495006 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report GI symptoms
Number of subjects: 223
Study 12905101 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ritanserin
Number of subjects: 134
Study 12905101 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ritanserin
Number of subjects: 134
Study 12905101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 10803508 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial systemic chemotherapy (prednisone, vincristine, doxorubicin, cyclophosphamide)
Number of subjects: 281
Study 8628601 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal phenobarbital (PB) therapy (10 mg/kg before delivery)
Number of subjects: 96
Study 8628601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PB therapy)
Number of subjects: 96
Study 8628601 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal phenobarbital (PB) therapy
Number of subjects: 96
Study 1629092 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating of the contralateral hand (60 degrees C) for 30 min before glucose intake
Number of subjects: 11
Study 1629092 — intervention group
Group type: COMPARATOR
Intervention: Control (no heating of the contralateral hand)
Number of subjects: 11
Study 1629092 — intervention group
Group type: EXPERIMENTAL
Intervention: Heating of the contralateral hand (60 degrees C)
Number of subjects: 11
Study 6338230 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire-mesh element within the 'buzzer and pad' enuresis alarm device
Number of subjects: 0
Study 31519779 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (IV tissue plasminogen activator)
Number of subjects: 121
Study 29754812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Contractility Modulation (CCM) for 24 weeks (n=74)
Number of subjects: 160
Study 29754812 — intervention group
Group type: COMPARATOR
Intervention: Continued medical therapy (control, n=86)
Number of subjects: 160
Study 27010160 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (TPM)
Number of subjects: 200
Study 27010160 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbital (PB)
Number of subjects: 200
Study 25590178 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin 250μg bolus injection before ERCP and 250μg/hour intravenous infusion for 11 hours after ERCP
Number of subjects: 900
Study 25590178 — intervention group
Group type: COMPARATOR
Intervention: No somatostatin treatments
Number of subjects: 900